SCHEMBL8442003

SCHEMBL8442003

CCCCCS(=O)(=O)Nc1cc(-c2cccc(C)c2C)ccc1O

nearest known ligand 0.58

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PGAM1 P18669 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10024271 0.81 PGAM1 (0.48) PGAM1
SCHEMBL12758262 0.76 KDM4E (0.56)
SCHEMBL10024295 0.76
SCHEMBL10024277 0.75
SCHEMBL14557527 0.75 MEN1 (0.49)
SCHEMBL10024272 0.74
SCHEMBL11442426 0.74 PGAM1 (0.52) PGAM1
SCHEMBL10024321 0.73
SCHEMBL10886862 0.73 PGAM1 (0.51) PGAM1
SCHEMBL14557528 0.72 KDM4E (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0966436-A1 ARYL SULFONAMIDES AND ANALOGUES THEREOF AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Bayer Aktiengesellschaft (DE) 1999-12-29 EP disclosed
WO-1998037061-A1 ARYL SULFONAMIDES AND ANALOGUES THEREOF AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES BAYER AKTIENGESELLSCHAFT (DE) 1998-08-27 WO disclosed